• Platform
  • Pipeline
    • Overview
    • Clinical Trial
  • Team
    • Leadership
    • Board of Directors
  • News
  • Careers

Kelonia Therapeutics Appoints Kristen Hege, M.D., and Mathai Mammen, M.D., Ph.D., to Board of Directors

by rob@robmaguiredesigns.com | Mar 28, 2024 | Press Releases

– World-renowned leaders in cell therapy, drug discovery and development join Kelonia as it moves toward early clinical development of in vivo CAR-T cell therapies – BOSTON, Mass., March 28, 2024 – Kelonia Therapeutics, a biotech company revolutionizing in vivo...

BioPharma: Astellas teams up with startup Kelonia to make ‘in vivo’ cell therapies

by rob@robmaguiredesigns.com | Feb 21, 2024 | News

GEN Edge: Astellas and Kelonia Partner for $800M In Vivo CAR T Cell Therapies

by rob@robmaguiredesigns.com | Feb 21, 2024 | News

Endpoint News: Astellas pursues ‘convertible’ in vivo CAR-T cell therapies with Kelonia Therapeutics

by rob@robmaguiredesigns.com | Feb 16, 2024 | News

Fierce Biotech: Astellas-owned Xyphos offers more than $800M for Kelonia’s in vivo delivery know-how

by rob@robmaguiredesigns.com | Feb 15, 2024 | News

« Older Entries
Next Entries »

Recent Posts

  • Kelonia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for KLN-1010, an in vivo BCMA CAR-T Therapy for Relapsed and Refractory Multiple Myeloma   
  • Kelonia Therapeutics Presents First-in-Human Data from Phase 1 inMMyCAR Study of KLN-1010 in vivo BCMA CAR-T Therapy at the American Society of Hematology (ASH) 2025 Annual Meeting  
  • Kelonia Therapeutics Announces Late-Breaking Oral Presentation of First-in-Human Data from in vivo BCMA CAR-T Therapy at the American Society of Hematology (ASH) 2025 Annual Meeting
  • Kelonia Therapeutics Enters into Strategic Collaboration with Johnson & Johnson to Advance in vivo CAR-T Therapies
  • Kelonia Therapeutics Doses First Patient in Phase 1 inMMyCAR Study Evaluating in vivo CAR T-Cell Therapy for Relapsed and Refractory Multiple Myeloma

Recent Comments

No comments to show.

Genetic Medicines for Every Patient.

  • Platform
  • Pipeline
    • Overview
    • Clinical Trial
  • Team
    • Leadership
    • Board of Directors
  • News
  • Careers




© 2025 KELONIA THERAPEUTICS, INC. ALL RIGHTS RESERVED.
PRIVACY POLICY. TERMS OF USE